How much do Pega boats cost on average?

The average asking price for a Pega boat is €4,861. Prices range from €3,584 to €6,880, depending on model, year of build and condition.

Where can I buy Pega boats in Europe?

On Obato.eu you will find 8 Pega boats for sale across the Netherlands, Belgium and Germany. You can contact sellers or dealers directly through our platform.

Are Pega boats of good quality?

Pega is known as a reputable boat builder. For specific information about quality, warranty and service, please contact official dealers or use Bo, our AI boat expert.

Pega trailer for sale

Name: Pega Boats
Brand: Pega
Availability: InStock

Verified

Portugal

Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. Outside the US pegaptanib is marketed by

boottrailers

Boats for sale

€3,584

From

€6,880

Up to

€4,861

Average price

Citable facts24 August 2026

Obato lists 8 Pega boats, ranging from €3,584 to €6,880.

Source: Obato Market Data

The average asking price for a Pega boat is €4,861.

Source: Obato Price Analysis

Current listings and prices

As of 24 August 2026: 8 active Pega listings on Obato. Asking prices range from €3,584 to €6,880 (median €4,641). Spread across roughly 6 distinct model variants. Figures come straight from the Obato database and are refreshed periodically.

About Pega

Pega (Portugal) is known for boottrailers. Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. Outside the US pegaptanib is marketed by